tim@emorningcoffee.com4 days ago9 minPortfolio update: 3Q2024This is the update of my personal portfolio for the most recent quarter ended September 30, 2024.
tim@emorningcoffee.comJul 248 minPortfolio update: 1H2024This is an update of my personal portfolio performance in 2Q2024 and 1H2024, good on the surface but worse than the indices would suggest.
tim@emorningcoffee.comMay 214 minIs fine wine a good investment? The 2024 en primeur campaign for Bordeaux is just starting. But is fine wine really a good investment? I don't think so anymore.
tim@emorningcoffee.comApr 108 minPortfolio update: 1Q2024This is an update about my personal portfolio during and at the end of 1Q2024. It also discusses performance which I consider disappointing.
tim@emorningcoffee.comMar 188 minAnti-obesity medications: part 3, valuations of LLY and NVOThis is the 3rd and final article focused on anti-obesity drugs. It looks at valuations of shares of the two giants in this biz, LLY & NVO.
tim@emorningcoffee.comMar 147 minAnti-obesity medications part 2: the duopoly of Eli Lilly and Novo NordiskEli Lilly (LLY) and Novo Nordisk (NVO) have been large players for decades in the market for diabetes medications and are currently...
tim@emorningcoffee.comMar 127 minAnti-obesity medications part 1: the market for anti-obesity drugsThis article is being published in instalments, of which this is the first, for context. INTRODUCTION Two macrotrends have been drivers...
tim@emorningcoffee.comMar 54 minRevisiting gold as an asset classThis is a guest post about gold, penned by online investment firm BullionVault. Gold has just pierced $2,100/oz, reaching a record high.
tim@emorningcoffee.comFeb 279 minBerkshire Hathaway: 2023 results and the path forwardBerkshire Hathaway released its FY earnings on Sat. As always, there are plenty of juicy nuggets to digest.